EGFR and spinal cord injury: In addition, Yan et al. [19] found that miR-325-3p attenuated secondary injury after spinal cord injury (SCI) by inhibiting the EGFR/MAPK signaling pathway, microglial activation, and the release of inflammatory cytokines, suggesting that miR-325-3p might be a useful therapeutic target for SCI.